Sarepta Therapeutics, Inc. Aktie News

Intellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments. Both biotechs have lost market value as a result, but both still seem too risky to consider investing in right now.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy (DMD). As previously disclosed, the ELEVIDYS label now includes several key updates, inclu...

The U.S. Food and Drug Administration said on Friday it approved new labeling for Sarepta Therapeutics' gene therapy Elevidys that includes its most serious safety warning and restricts use of the treatment to walking patients with Duchenne muscular dystrophy.

Sarepta Therapeutics, Inc. faces uncertainty after Elevidys' revenue decline and ESSENCE trial failure, leading to a 25% SRPT stock drop. SRPT's PMO franchise remains its cash engine, but regulatory reliance on real-world evidence and FDA unpredictability add risk to the investment thesis. Label contraction for Elevidys and margin pressures weigh on near-term outlook, with upside catalysts most...

Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance.

Sarepta Therapeutics Inc. shares plunged 37% on Tuesday after the biotechnology company reported disappointing trial results for two of its treatments targeting Duchenne muscular dystrophy (DMD). The stock fell to $15.28 on Tuesday's open, compounding a steep 80% decline in 2025 before the latest selloff.

The biotechnology company discloses disappointing trial data for two treatments for Duchenne muscular dystrophy.

Sarepta Therapeutics, Inc. ( SRPT ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Tamara Thornton Douglas Ingram - CEO & Director Louise Rodino-Klapac - President of Research & Development and Technical Operations Patrick Moss - Executive VP & Chief Commercial Officer Ryan Wong - Executive VP & CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Researc...